Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Avalo Therapeutics, Inc. - Common Stock (NQ:AVTX)

14.59 -1.38 (-8.62%)
Streaming Delayed Price Updated: 3:46 PM EST, Feb 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Avalo Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Avalo Therapeutics to Participate in Upcoming Investor Conferences
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics to Participate in Upcoming Investor Conferences
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics to Participate in Upcoming Investor Conferences
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics to Participate in Upcoming Investor Conferences
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics to Participate in Upcoming Investor Conferences
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics to Participate in The Citizens Life Sciences Conference
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Reports 2024 Financial Results and Recent Business Updates
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics to Participate in Upcoming Investor Conferences
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics to Present at Upcoming Investor Conferences
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Announces Participation in September Investor Conferences
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
From Avalo Therapeutics
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.